294 related articles for article (PubMed ID: 30938616)
21. Canine Apocrine Gland Anal Sac Adenocarcinoma: A Review.
Repasy AB; Selmic LE; Kisseberth WC
Top Companion Anim Med; 2022; 50():100682. PubMed ID: 35792243
[TBL] [Abstract][Full Text] [Related]
22. Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of gastrointestinal stromal tumors of dogs.
Berger EP; Johannes CM; Jergens AE; Allenspach K; Powers BE; Du Y; Mochel JP; Fox LE; Musser ML
J Vet Intern Med; 2018 Nov; 32(6):2045-2053. PubMed ID: 30307656
[TBL] [Abstract][Full Text] [Related]
23. Adherence to follow-up recommendations for dogs with apocrine gland anal sac adenocarcinoma: A multicentre retrospective study.
Chambers AR; Skinner OT; Mickelson MA; Schlag AN; Butler JR; Wallace ML; Moyer AL; Vinayak A; Samuel N; Kennedy KC; Oakes KE; Scharf VF; Parker LA; Wustefeld-Janssens BG
Vet Comp Oncol; 2020 Dec; 18(4):683-688. PubMed ID: 32266757
[TBL] [Abstract][Full Text] [Related]
24. The role of toceranib phosphate in dogs with non-mast cell neoplasia: A systematic review.
Frezoulis P; Harper A
Vet Comp Oncol; 2022 Jun; 20(2):362-371. PubMed ID: 34981886
[TBL] [Abstract][Full Text] [Related]
25. Retrospective evaluation of toceranib (Palladia) treatment for canine metastatic appendicular osteosarcoma.
Kim C; Matsuyama A; Mutsaers AJ; Woods JP
Can Vet J; 2017 Oct; 58(10):1059-1064. PubMed ID: 28966355
[TBL] [Abstract][Full Text] [Related]
26. Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of inoperable, metastatic, or recurrent canine pheochromocytomas: 5 dogs (2014-2017).
Musser ML; Taikowski KL; Johannes CM; Bergman PJ
BMC Vet Res; 2018 Sep; 14(1):272. PubMed ID: 30176869
[TBL] [Abstract][Full Text] [Related]
27. Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma.
Gardner HL; London CA; Portela RA; Nguyen S; Rosenberg MP; Klein MK; Clifford C; Thamm DH; Vail DM; Bergman P; Crawford-Jakubiak M; Henry C; Locke J; Garrett LD
BMC Vet Res; 2015 Jun; 11():131. PubMed ID: 26062540
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of palliative therapy, alone or in combination with toceranib phosphate, in dogs diagnosed with metastatic or recurrent beta-cell neoplasia.
Alonso-Miguel D; García-San José P; González Sanz S; Clarés Moral I; Pérez-Alenza MD
N Z Vet J; 2021 Jul; 69(4):234-239. PubMed ID: 33944682
[TBL] [Abstract][Full Text] [Related]
29. Surgery of metastatic anal sac adenocarcinoma in five dogs.
Hobson HP; Brown MR; Rogers KS
Vet Surg; 2006 Apr; 35(3):267-70. PubMed ID: 16635006
[TBL] [Abstract][Full Text] [Related]
30. Post-operative complications following apocrine gland anal sac adenocarcinoma resection in dogs.
Sterman A; Butler JR; Chambers A; Dickson R; Dornbusch J; Mickelson M; Selmic L; Scharf V; Schlag A; Skinner O; Vinayak A; Janssens BW
Vet Comp Oncol; 2021 Dec; 19(4):743-749. PubMed ID: 34173318
[TBL] [Abstract][Full Text] [Related]
31. Expression of PDGFR-β and Kit in canine anal sac apocrine gland adenocarcinoma using tissue immunohistochemistry.
Brown RJ; Newman SJ; Durtschi DC; Leblanc AK
Vet Comp Oncol; 2012 Mar; 10(1):74-9. PubMed ID: 22235855
[TBL] [Abstract][Full Text] [Related]
32. Effects of Toceranib Phosphate on Systolic Blood Pressure and Proteinuria in Dogs.
Tjostheim SS; Stepien RL; Markovic LE; Stein TJ
J Vet Intern Med; 2016 Jul; 30(4):951-7. PubMed ID: 27149912
[TBL] [Abstract][Full Text] [Related]
33. Minimal complications observed with a modified surgical approach for treatment of canine anal sac neoplasia.
Chen CL; Lapsley JM; Selmic LE
J Am Vet Med Assoc; 2021 Dec; 260(S1):S59-S64. PubMed ID: 34914627
[TBL] [Abstract][Full Text] [Related]
34. Retrospective evaluation of toceranib phosphate (Palladia) in the treatment of canine carcinomatosis and mesothelioma.
Hicks KA; Leeper HJ; Curran KM
Vet Comp Oncol; 2024 Jun; 22(2):245-254. PubMed ID: 38622074
[TBL] [Abstract][Full Text] [Related]
35. Anal sac tumours of the dog and their response to cytoreductive surgery and chemotherapy.
Emms SG
Aust Vet J; 2005 Jun; 83(6):340-3. PubMed ID: 15986909
[TBL] [Abstract][Full Text] [Related]
36. Temporally separated bilateral anal sac gland carcinomas in four dogs.
Bowlt KL; Friend EJ; Delisser P; Murphy S; Polton G
J Small Anim Pract; 2013 Aug; 54(8):432-6. PubMed ID: 23659267
[TBL] [Abstract][Full Text] [Related]
37. Minimal late radiation toxicity and transient early toxicity following postoperative definitive intent conformal radiation therapy (20 × 2.5 Gy) for canine apocrine gland anal sac adenocarcinoma.
Williams C; Parys M; Handel I; Serra JC; Lawrence J
Vet Radiol Ultrasound; 2022 Mar; 63(2):224-233. PubMed ID: 34904326
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetic properties of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors.
Yancey MF; Merritt DA; Lesman SP; Boucher JF; Michels GM
J Vet Pharmacol Ther; 2010 Apr; 33(2):162-71. PubMed ID: 20444041
[TBL] [Abstract][Full Text] [Related]
39. Three-dimensional conformal versus non-graphic radiation treatment planning for apocrine gland adenocarcinoma of the anal sac in 18 dogs (2002-2007).
Keyerleber MA; Gieger TL; Erb HN; Thompson MS; McEntee MC
Vet Comp Oncol; 2012 Dec; 10(4):237-45. PubMed ID: 22235910
[TBL] [Abstract][Full Text] [Related]
40. A prospective, multi-centre, Veterinary Radiation Therapy Oncology Group study reveals potential efficacy of toceranib phosphate (Palladia) as a primary or adjuvant agent in the treatment of canine nasal carcinoma.
Ehling TJ; Klein MK; Smith L; Prescott D; Haney S; Looper J; LaDue T; Brawner W; Fidel J; Shiomitsu K; Green E; Saba C; Turek M; Farrelly J
Vet Comp Oncol; 2022 Mar; 20(1):293-303. PubMed ID: 34655275
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
